Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Mina Iwai"'
Autor:
Takuma Minoura, Jun Yaokawa, Hiroaki Iwahori, Yuko Aoki, Mina Iwai, Shuxin Dong, Yasushi Iwata
Publikováno v:
MATERIALS TRANSACTIONS. 63:1258-1265
Autor:
Masahito Shiozawa, Kosuke Kitazumi, Mina Iwai, Shintaro Mizuno, Naohiko Kato, Yasuhiko Takeda, Tsuyoshi Hamaguchi
Publikováno v:
Electrocatalysis. 13:830-837
Autor:
Saeko, Taga, Hiroki, Asano, Mina, Iwai, Shoya, Takenaka, Akihiro, Moriya, Takashi, Otsuka, Michio, Kimura, Tomoaki, Yoshimura
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 49(10)
A new nivolumab and pembrolizumab monotherapy regimen with double the conventional dose and longer dosing intervals( the new regimen)has been approved. Here, we report the incidence of immune-related adverse events(irAEs)in the early phase of switchi
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 49(6)
The addition of anti-angiogenic agents to cytotoxic agents to improve outcomes has become the standard treatment for metastatic colorectal carcinoma. In this study, we evaluated the safety of bevacizumab plus FOLFIRI with that of ramucirumab plus FOL
Autor:
Sho Toshino, Mina Iwai
Publikováno v:
Biogeography; 2021, Vol. 23, p33-36, 4p
Autor:
MINA IWAI1,2 mina_i0913@yahoo.co.jp, MICHIO KIMURA1, EISEKI USAMI1, TOMOAKI YOSHIMURA3, HITOMI TERAMACHI1
Publikováno v:
Molecular & Clinical Oncology. 2017, Vol. 6 Issue 5, p794-798. 5p.
Autor:
Hiroki Asano, Makiko Go, Tomoaki Yoshimura, Mina Iwai, Michio Kimura, Shoya Takenaka, Eiseki Usami, Shino Adachi
Publikováno v:
Journal of Oncology Pharmacy Practice. 25:869-874
Introduction Pegfilgrastim is a PEGylated formulation of filgrastim with a long half-life. It is highly convenient and less burdensome for patients. However, white blood cell count may temporarily increase after administration; in particular, a leuko
Autor:
Mina, Iwai
Publikováno v:
玉藻. 52:103-127
Publikováno v:
Molecular and Clinical Oncology. 6:955-959
The purpose of this study was to assess the incidence of tumor lysis syndrome (TLS) in patients with hematological malignancies treated with rasburicase, and to evaluate the dose and duration of rasburicase administration. A total of 52 patients were
Publikováno v:
Molecular and Clinical Oncology. 6:794-798
Comparison of the costs of capecitabine plus oxaliplatin (CapeOX) with that of FOLFOX6 (5-fluorouracil/leucovorin [LV] + oxaliplatin) as an adjuvant chemotherapy for stage II or III colorectal cancer has previously been reported. However, there are n